Trikafta, the only Vertex drug tracked here, made $10.3B of its 2025 revenue (86%) and loses US exclusivity in 2037. Since 2023, Vertex has closed 2 acquisitions of $1B or more, worth $14.9B in total.
Bars are each drug's 2025 sales as a share of Vertex’s total revenue ($12.0B). Only drugs tracked here are counted, so full exposure can be higher. Tap a bar for the drug's page.
| Closed | Company bought | Value | Area | What it brought | At closing |
|---|---|---|---|---|---|
| May 2024 | Alpine Immune SciencesAlpine, April 2024 · Vertex, 2024 | $4.9B | Other | Povetacicept, a drug for IgA nephropathy, a kidney disease | Pipeline only |
| Sep 2026 | Crinetics PharmaceuticalsVertex, July 2026 · Vertex, September 2026 | $10.0B | Other | Palsonify for acromegaly, a hormone disorder, plus other endocrine drugs in development | Approved product |
| 2 counted | $14.9B | ||||
Acquisitions of whole companies closed since January 2023 with a headline price of $1B or more. Values are the price Vertex announced, excluding milestone payments unless noted. Licensing deals are not included. Compare all 65 deals →
| Area | At risk by 2037 | Acquisitions since 2023 |
|---|---|---|
| Other | $10.3B | $14.9B |
Other is where Vertex has the most revenue at risk and where it has spent the most on acquisitions. At risk is 2025 sales of tracked drugs losing US exclusivity by 2037; acquisitions are the headline value of counted deals closed since 2023.
The two figures measure different things. Revenue at risk is what the drugs earned in 2025. A deal's value is what Vertex paid, not the sales it will bring in. Only one of the 2 companies it bought was already selling an approved product at closing (Crinetics Pharmaceuticals); the rest brought pipeline drugs whose sales are years away and may never arrive. So this page shows the figures side by side rather than claiming how much of the gap the deals fill.
Revenue: Vertex FY2025. Drug sales and dates are sourced on each drug's page; each deal links to Vertex’s announcement or filing in the table above.
See all 45 drugs on the patent cliff →